Analysis of Pancreatic Cancer Intestinal Tissue Microbiota Structure and Pathogens Based on Microbiome Data

Research Article

Austin J Microbiol. 2024; 9(2): 1050.

Analysis of Pancreatic Cancer Intestinal Tissue Microbiota Structure and Pathogens Based on Microbiome Data

Hao Dong¹; Yuqi Wang¹; Linlin Lu²*; Xuezhen Ma³*

1College of Medicine, Qingdao University, Qingdao 266071, China

2Qingdao Cancer Prevention and Treatment Research Institute, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao 266042, China

3Cancer Center, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao 266042, China

*Corresponding author: Xuezhen Ma Cancer Center, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao 266042, China; Linlin Lu, Qingdao Cancer Prevention and Treatment Research Institute, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao 266042, China, Email: 18660229289@163.com; 18266208011@163.com

Received: March 19, 2024 Accepted: April 24, 2024 Published: May 01, 2024

Abstract

Objective: This study aims to investigate the impact of pancreatic cancer on the gut microbiota structure in adults by analyzing the diversity and composition changes of microbes, and to explore the relationship between pancreatic cancer and intestinal microbiota.

Results: The study demonstrated significant differences in the microbiota structure between pancreatic cancer patients and healthy individuals. Changes in microbial diversity and composition were confirmed through a-diversity and β-diversity analyses. A random forest model presented the gut-related microbial community patterns. The Microbial Infection Potential (MIP) indicated variations in pathogen numbers under different conditions.

Methods: Fecal samples from healthy individuals and pancreatic cancer patients were collected for microbial community structure comparison using 16S rRNA gene sequencing. The changes in microbial composition and pathogen characteristics were revealed through a-diversity and β-diversity analyses, as well as metagenomic analysis.

Conclusion: This study not only elucidated the impact of pancreatic cancer on intestinal microbiota but also suggested its potential role in the development of pancreatic cancer. Understanding these interactions may help discover new biomarkers, therapeutic targets, and personalized treatment strategies. Future research will explore the clinical application potential of these microbiomes in the treatment of pancreatic cancer and further reveal underlying mechanisms.

Keywords: Molecular Biology; Microbiome; Pancreatic Neoplasm

Introduction

Pancreatic cancer, a devastating malignancy with a poor prognosis, has been increasingly linked to alterations in the gut microbiota. The intricate relationship between pancreatic cancer and the intestinal microbiome is gaining attention for its potential role in cancer development, progression, and treatment response. This paper aims to delve into the complexities of this relationship by analyzing the microbiota structure and identifying key pathogens in pancreatic cancer patients.

The gut microbiota, a complex ecosystem of microorganisms, plays a crucial role in human health, influencing metabolism, immunity, and even the efficacy of cancer therapies [1,2]. In pancreatic cancer, the microbiota undergoes significant changes, characterized by reduced microbial diversity and an increase in pathogenic bacteria [3]. These dysbiotic alterations can trigger persistent inflammation, modulate the tumor microenvironment, and potentially contribute to carcinogenesis [4,5].

Recent studies have highlighted the distinct gut microbiome profiles in pancreatic cancer patients, with a decrease in butyrate-producing bacteria and an increase in harmful genera like Fusobacterium, Enterobacter, and Enterococcus [6]. This shift in microbial composition may influence the host's immune response and increase the risk of cancer development [7]. Furthermore, the microbiota's role extends to affecting the outcome and survival of patients, particularly those undergoing immunotherapy [8].

The interaction between pancreatic cancer and the gut microbiota is bidirectional. Pancreatic factors, such as antimicrobial excretion, can impact the composition and functional properties of the gut microbiota [9]. Moreover, an altered oral microbiota may colonize the pancreas, causing local inflammation and contributing to cancer development [10].

Understanding the correlation between gut microbiota and pancreatic cancer could aid in diagnosis, treatment, and the development of new therapeutic strategies, including the use of probiotics, antibiotics, and fecal microbiota transplantation [11]. This study aims to further elucidate these interactions, offering insights into the potential role of intestinal microbiota in the development and treatment of pancreatic cancer.

Results

Sample Description

This paper studied 180 human intestinal microbiome samples, including 74 samples from healthy adults, 88 samples from patients with pancreatic cancer, and 18 samples from adults in the early stages of pancreatic cancer. All samples were sourced from the NCBI public open-access database.

Microbial Diversity in Healthy Samples, Pancreatic Cancer Samples, and Early-Stage Pancreatic Cancer Samples

After a series of processing steps, this study obtained 180 samples from three different states: healthy young individuals, pancreatic cancer patients, and early-stage pancreatic cancer patients, amounting to a total of 960,210 high-quality sequences. Among these, 74 samples were from healthy young individuals, 88 from pancreatic cancer patients, and 18 from non-tumor-invaded individuals. Species resolution of sequencing data was performed using the Greengenes 13-8 reference database, resulting in 10,669 OTUs. Venn diagram (Figure 1a) showed that the healthy group and pancreatic cancer group shared 4,259 OTUs (39.92%), the healthy group and early-stage pancreatic cancer shared 110 OTUs (1.03%), and the pancreatic cancer group and early-stage pancreatic cancer shared 206 OTUs (1.93%), with a total of 1,171 OTUs (10.98%) shared among all three states. The pancreatic cancer group had 2,311 unique OTUs (21.66%), the healthy group had 2,000 unique OTUs (18.75%), and the early-stage pancreatic cancer group had 612 unique OTUs (5.73%). Twelve phyla were identified across the healthy, pancreatic cancer, and early-stage groups, with Proteobacteria being the dominant phylum in all three groups (45.10%, 37.10%, and 47.96% respectively), followed by Firmicutes (25.16%, 28.80%, and 28.91%). A total of 100 genera were detected in the healthy and pancreatic cancer groups, and 93 genera in the early-stage pancreatic cancer group. Prevotella was the dominant genus in both the healthy and pancreatic cancer groups (20.15% and 18.70% respectively). Pseudomonas was the dominant genus in the early-stage pancreatic cancer group (40.59%), and the second most prevalent genus in the pancreatic cancer group (13.26%). Streptococcus was the second most prevalent genus in both the healthy and early-stage pancreatic cancer groups (15.46% and 13.93%).